Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Hydroxyurea therapy for sickle cell disease in community‐based practices: A survey of Florida and North Carolina hematologists/oncologists2005 · 81 citations
2. 2The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)2009 · 439 citations
3. 3DNA polymorphisms at the <i>BCL11A</i> , <i>HBS1L-MYB</i> , and β- <i>globin</i> loci associate with fetal hemoglobin levels and pain crises in sickle cell disease2008 · 552 citations
4. 4Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia2007 · 219 citations
5. 5Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia1995 · 2,366 citations